Medicare Enrolled
Dr. Gary Shi, MD, PHD
Hematology & Oncology · Jackson, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shi
Dr. Gary Shi is a hematology & oncology specialist in Jackson, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Shi performed 64,720 Medicare services across 1,224 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shi received a total of $16,270 from 49 pharmaceutical and/or device companies across 202 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 12% volume in CA
$16,270 industry payments
Medicare Practice Summary
Medicare Utilization ↗64,720
Medicare services
Top 12% in CA for hematology & oncology
1,224
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,236 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 13,920 | $18 | $30 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
12,380 | $6 | $12 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,300 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 6,504 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
5,130 | $0 | $1 |
| Injection, potassium chloride, per 2 meq | 5,000 | $0 | $1 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
2,129 | $13 | $50 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,225 | $102 | $170 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
1,118 | $1 | $2 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
1,112 | $24 | $80 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
880 | $11 | $50 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
824 | $11 | $40 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
792 | $70 | $120 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
592 | $17 | $50 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
550 | $1 | $2 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
535 | $1 | $5 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
497 | $1 | $3 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
494 | $25 | $70 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
371 | $111 | $300 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
332 | $17 | $50 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
320 | $1 | $3 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
203 | $54 | $151 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 194 | $14 | $25 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
187 | $55 | $140 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
77 | $2 | $5 |
| New patient office visit, complex (60-74 min) | 43 | $175 | $300 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
11 | $147 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.3% high complexity
90.5% medium
5.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,270
Total received (2018-2024)
Avg $2,324/year across 7 years
Top 25% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
202
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,698 (65.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,131 (25.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,441 (8.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$807
2023
$11,655
2022
$893
2021
$491
2020
$82
2019
$1,602
2018
$740
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$421
Incyte Corporation
$100
PFIZER INC.
$56
ABBVIE INC.
$42
E.R. Squibb & Sons, L.L.C.
$29
Genentech USA, Inc.
$27
Biocon Biologics Inc
$27
Novartis Pharmaceuticals Corporation
$24
SpringWorks Therapeutics, Inc.
$24
Sumitomo Pharma America, Inc.
$22
SERVIER PHARMACEUTICALS LLC
$22
Astellas Pharma US Inc
$16
Top 3 companies account for 71.4% of 2024 payments
All-time payments by company (2018-2024) ›
ADC Therapeutics America, Inc.
$10,698
E.R. Squibb & Sons, L.L.C.
$589
Genentech USA, Inc.
$504
Lilly USA, LLC
$421
Astellas Pharma US Inc
$410
Janssen Biotech, Inc.
$376
PFIZER INC.
$313
Amgen Inc.
$252
Novartis Pharmaceuticals Corporation
$245
AstraZeneca Pharmaceuticals LP
$244
Celgene Corporation
$225
Incyte Corporation
$225
GENZYME CORPORATION
$195
Seagen Inc.
$181
Seattle Genetics, Inc.
$125
SANOFI-AVENTIS U.S. LLC
$125
Merck Sharp & Dohme Corporation
$95
MorphoSys, US Inc.
$73
SERVIER PHARMACEUTICALS LLC
$69
TerSera Therapeutics LLC
$67
Eisai Inc.
$65
Pharmacyclics LLC, An AbbVie Company
$60
ABBVIE INC.
$55
Kite Pharma, Inc.
$52
BIOTRONIK INC.
$44
Mirati Therapeutics, Inc.
$44
Myovant Sciences Inc.
$40
Merck Sharp & Dohme LLC
$35
GE HealthCare
$32
BeiGene USA, Inc.
$30
Boston Scientific Corporation
$30
EMD Serono, Inc.
$29
Biocon Biologics Inc
$27
Deciphera Pharmaceuticals Inc.
$26
Teva Pharmaceuticals USA, Inc.
$26
Bayer HealthCare Pharmaceuticals Inc.
$25
SpringWorks Therapeutics, Inc.
$24
Servier Pharmaceuticals LLC
$22
JAZZ PHARMACEUTICALS INC.
$22
Sumitomo Pharma America, Inc.
$22
ARRAY BIOPHARMA INC
$21
EISAI INC.
$17
Agios Pharmaceuticals, Inc.
$16
Bayer Healthcare Pharmaceuticals Inc.
$15
AbbVie Inc.
$14
Karyopharm Therapeutics Inc.
$13
Mylan Pharmaceuticals Inc.
$12
Helsinn Therapeutics (U.S.), Inc.
$11
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 72.5% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · Avastin · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · DARZALEX · ELIQUIS · EMPLICITI · ERLEADA · Erleada · Fulphila · GAZYVA · GENERAL BRADY · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LUPRON DEPOT · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · Nplate · Nubeqa · OGSIVEO · ONUREG · OPDIVO · ORGOVYX · Ogivri · PROMACTA · Perjeta · Pomalyst · Prolia · QINLOCK · RYBREVANT · Revlimid · SARCLISA · SCEMBLIX · SPRYCEL · TALZENNA · TASIGNA · TECENTRIQ · TIBSOVO · Tibsovo · VENCLEXTA · VERZENIO · Venclexta · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (66%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
3
Per 100K population
7.3
County median income
$81,526
Nearest hospital
SUTTER AMADOR HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shi is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with consulting-driven industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shi experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Shi performed 13,920 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shi receive payments from pharmaceutical companies?
Yes. Dr. Shi received a total of $16,270 from 49 companies across 202 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shi's costs compare to other hematology & oncology specialists in Jackson?
Dr. Shi's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jackson
Browse hematology & oncology specialists in Jackson ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
ADC Therapeutics America, Inc. Payments to Doctors
See all physicians who received payments from ADC Therapeutics America, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology